# A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

> **NCT00091624** · PHASE1 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 77 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013

## Key facts

- **NCT ID:** NCT00091624
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091624, "A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00091624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*